Its therapeutic effect includes blockade of HER2 signaling through p42/p44 MAPK and PI3K/Akt pathways, inhibition of HER2 shedding, downregulation of HER2 availability, inhibition of tumor angiogenesis, and ADCC (217, 250–254). Here, ERBB2 is linked to neoplasm.